MedTrace Logo

PulseHaler Drug Deposition Study in Chronic Obstructive Pulmonary Disease Patients

NCT01187589 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-09-23

No results posted yet for this study

Summary

This study is aimed at finding the effect of PulseHaler™ with Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients

Conditions

Interventions

DEVICE

Pulsehaler

DRUG

Nebulizer & Albuterol 0.5ml

Albuterol aerosolized by a nebulizer

Sponsors & Collaborators

  • Respinova LTD

    lead INDUSTRY

Principal Investigators

  • Haim Golan, MD · Assaf Harofe Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01187589 on ClinicalTrials.gov